Loxo Oncology Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Stamford CT United States (2010)
Status: Acquired by Eli Lilly (2019)

Organization Overview

First Clinical Trial
2014
NCT02122913
First Marketed Drug
2018
larotrectinib (vitrakvi)
First NDA Approval
2018
larotrectinib (vitrakvi)
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

LOXO ONCOL | Loxo Oncology | LOXO Oncology | Loxo Oncology, Inc. | LOXO ONCOLOGY INC | Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company | Loxo Oncology Medical Monitor, VP of R&D | Senior Medical Director, Loxo Oncology

Active Ingredients

Marketed Drugs (3)

larotrectinib (vitrakvi) (2018 NDA)

pirtobrutinib (Jaypirca) (2023)

Selpercatinib (Retevmo) (2020)

Drugs in Phase 3 Trials (16)

acalabrutinib (calquence) (1 trial)

bendamustine (treanda) (2 trials)

cabozantinib (cometriq) (1 trial)

carboplatin (paraplatin) (2 trials)

cisplatin (platinol) (2 trials)

ibrutinib (imbruvica) (2 trials)

idelalisib (zydelig) (1 trial)

ly3537982 (6 trials)

pembrolizumab (keytruda) (3 trials)

pemetrexed (alimta) (2 trials)

pirtobrutinib (Jaypirca) (19 trials)

rituximab (rituxan) (3 trials)

Selpercatinib (Retevmo) (21 trials)

vandetanib (caprelsa) (1 trial)

venetoclax (venclexta) (3 trials)

zanubrutinib (Brukinsa) (1 trial)

Drugs in Phase 2 Trials (7)

allopurinol (zyloprim) (1 trial)

larotrectinib (vitrakvi) (4 trials)

obinutuzumab (gazyva) (1 trial)

omeprazole (prilosec) (3 trials)

ranitidine (zantac) (1 trial)

selitrectinib (1 trial)

valaciclovir (Valtrex) (1 trial)

Drugs in Phase 1 Trials (28)

abemaciclib (verzenio) (2 trials)

anastrozole (arimidex) (1 trial)

carbamazepine (tegretol) (2 trials)

cetuximab (erbitux) (1 trial)

cholestyramine (questran) (1 trial)

dabigatran (pradaxa) (1 trial)

digoxin (lanoxin) (1 trial)

erlotinib (tarceva) (1 trial)

esomeprazole (nexium) (1 trial)

exemestane (aromasin) (1 trial)

fulvestrant (faslodex) (1 trial)

imlunestrant (1 trial)

itraconazole (sporanox) (4 trials)

letrozole (femara) (1 trial)

loxo-260 (2 trials)

loxo-338 (1 trial)

loxo-435 (1 trial)

loxo-783 (4 trials)

ly3214996 (1 trial)

ly3295668 (1 trial)

ly3410738 (5 trials)

midazolam (versed) (3 trials)

moxifloxacin (avelox) (1 trial)

paclitaxel (taxol) (1 trial)

repaglinide (prandin) (2 trials)

rifampin (2 trials)

rosuvastatin (crestor) (2 trials)

sintilimab (1 trial)

Drugs in Other Trials (1)

loxo-195 (1 trial)

Indications

Approved Indications


 

Neoplasms

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Stem Neoplasms (Phase 2)

Carcinoma, Neuroendocrine (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Central Nervous System Neoplasms (Phase 2)

Cholangiocarcinoma (Phase 1)

Chondrosarcoma (Phase 1)

Colonic Neoplasms (Phase 1)

Fibrosarcoma (Phase 2)

Glioma (Phase 1)

Hematologic Neoplasms (Phase 1)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)

Leukemia, Lymphoid (Phase 3)

Leukemia, Myeloid, Acute (Phase 1)

Leukemia, Myelomonocytic, Chronic (Phase 1)

Leukemia, Myelomonocytic, Juvenile (Phase 1)

Lung Neoplasms (Phase 3)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 2)

Lymphoma, B-Cell, Marginal Zone (Phase 2)

Lymphoma, Mantle-Cell (Phase 3)

Myelodysplastic Syndromes (Phase 1)

Myeloproliferative Disorders (Phase 1)

Myofibromatosis (Phase 2)

Neoplasms (Phase 2)

Nervous System Neoplasms (Phase 2)

Preleukemia (Phase 1)

Sarcoma (Phase 2)

Thyroid Cancer, Papillary (Phase 2)

Thyroid Diseases (Phase 3)

Thyroid Neoplasms (Phase 3)

Waldenstrom Macroglobulinemia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 64
  • # of Trial APIs: 52